Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Scientists at UC San Francisco have pioneered a groundbreaking approach to fighting cancer using engineered fat cells. By ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Cancer is rarely discussed alongside liposuction or plastic surgery. However, a groundbreaking approach to cancer treatment ...

The Global Stem Cell Therapy For Diabetes Related Conditions market industry is primarily driven by the continuous advancements in technology.

CRISPR (NASDAQ:CRSP) develops gene-based medicines using its CRISPR/Cas9 platform, with therapies targeting diseases like ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Visualizing cells after editing specific genes can help scientists learn new details about the function of those genes. But ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...